These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6422975)

  • 1. Response of factor XII to DDAVP in patients with Hageman factor deficiency.
    Gamba G; Grignani G; Longoni P; Ascari E
    Br J Haematol; 1983 Dec; 55(4):713-5. PubMed ID: 6422975
    [No Abstract]   [Full Text] [Related]  

  • 2. [Response to DDAVP in von Willebrand disease type II C].
    Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
    Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of DDAVP on plasma level of factor XII.
    Nenci GG; Berrettini M; De Cunto M; Agnelli G
    Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of desmopressin (DDAVP) in the preparation of improved factor VIII concentrate.
    Mikaelsson M; Nilsson IM; Cedergren B; Jonsson S; Rydberg L; Wiechel B
    Scand J Haematol Suppl; 1984; 40():93-101. PubMed ID: 6433478
    [No Abstract]   [Full Text] [Related]  

  • 5. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
    Vicente V; Alberca I; Mannucci PM
    Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with deamino-8-D-AGR-Vasopressin (DDAVP) in patients with Factor VIII deficiency.
    Sweeney JD; Crosby P; McCann SR; Temperley IJ
    Ir J Med Sci; 1981 Aug; 150(8):236-9. PubMed ID: 6974718
    [No Abstract]   [Full Text] [Related]  

  • 9. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.
    Kobrinsky NL; Doyle JJ; Israels ED; Winter JS; Cheang MS; Walker RD; Bishop AJ
    Lancet; 1985 Jun; 1(8441):1293-4. PubMed ID: 2860491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDAVP in haemophilia and von Willebrand's disease.
    Lancet; 1983 Oct; 2(8353):774-5. PubMed ID: 6137606
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor.
    de la Fuente B; Panek S; Hoyer LW
    Br J Haematol; 1985 Jan; 59(1):127-31. PubMed ID: 3918556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desamino-D-arginine vasopressin and bleeding time in von Willebrand's disease.
    Isola L; Forster A; Aledort LM
    Ann Intern Med; 1984 Nov; 101(5):719-20. PubMed ID: 6435493
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors.
    Palmer DS; Harris AS; Tittley P; Rock G
    Haemostasis; 1988; 18(3):187-96. PubMed ID: 2972594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DDAVP: alternative therapy in moderate pathology of Factor VIII/von Willebrand].
    Vicente V; Alberca I; Moraleda JM; López Borrasca A
    Sangre (Barc); 1983; 28(4):531-2. PubMed ID: 6606856
    [No Abstract]   [Full Text] [Related]  

  • 15. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.
    Brommer EJ; Derkx FH; Barrett-Bergshoeff MM; Schalekamp MA
    Thromb Haemost; 1984 Feb; 51(1):42-4. PubMed ID: 6426080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The position of a vasopressin derivative ("DDAVP") in the treatment of haemophilia A (author's transl)].
    Blättler W; Jacky E; Müller M; Graf M; Meili E
    Ther Umsch; 1979 Apr; 36(4):330-3. PubMed ID: 377557
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure.
    Watson AJ; Keogh JA
    Nephron; 1982; 32(1):49-52. PubMed ID: 6817151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
    Mannucci PM; Canciani MT; Rota L; Donovan BS
    Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmopressin (dDAVP): a powerful general hemostatic agent?
    Drouet L; Scrobohaci ML; Boudaoud S; Vilain G
    Nouv Rev Fr Hematol (1978); 1989; 31(2):163-5. PubMed ID: 2528120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.